April 1, 2020
It was supposed to be an exciting time of next-gen science, where CRISPR gene editing was being used in the first series of human trials in the hope this tech could help cure a range of diseases.
But one of its proponents, CRISPR Therapeutics, has, alongside a growing number of biopharmas, admitted the spreading COVID-19 pandemic is starting to see it be “adversely affected.”
In a Securities and Exchange Commission filing Tuesday, the biotech said: “We are conducting a number of clinical trials for product candidates in the fields of severe hemoglobinopathies and immuno-oncology in geographies which are affected by the coronavirus pandemic.
Comments are closed.